Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine

EPMA Journal

Volumn 1, Issue 1, 2010, Pages 3-12

  Golubnitschaja, Olga ^a,b  

^a European Association for Predictive Preventive and Personalised Medicine   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Advanced technologies; Education; Healthcare providers; Navigating diagnostic systems; Socioeconomical aspects; Strategic trends

Indexed keywords

ACCURACY; ARTICLE; COST OF ILLNESS; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEALTH PROMOTION; HIGH RISK PATIENT; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREDICTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SOCIAL INTERACTION; TREATMENT PLANNING; TREND STUDY; VALIDATION PROCESS;

EID: 77957562031     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0014-5     Document Type: Article

References (68)

1. Costigliola V, Gahan P, Golubnitschaja O. Predictive Medicine as the New Philosophy in Healthcare. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
2. Golubnitschaja O. Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment. Curr Diabetes Rev. 2010;6:42-51.
3. RosenbloomAL, Joe JR,Young RS,WinterWE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22:345-54.
4. Huang TT, Goran MI. Prevention of type 2 diabetes in young people: a theoretical perspective. Pediatr Diabetes. 2003;4:38-56.
5. Golubnitschaja O. Clinical Proteomics in application to predictive diagnostics and personalized treatment of diabetic patients. Current Proteomics. 2008;5:35-44.
6. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infect Disord Drug Targets. 2008;8:76-87.
7. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a Risk Factor for Cancer: Is Predictive Diagnosis Possible? In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
8. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123-32.
9. Golubnitschaja O. Diabetes mellitus. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.
11. Peeva V, Golubnitschaja O. Birth Asphyxia as the Most Frequent Perinatal Complication. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
12. Yeghiazaryan K, Peeva V, Morelli M, et al. Potential Targets for Early Diagnosis and Neuroprotection in Asphyxiated Newborns. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
13. Dunlop BW, Sternberg M, Phillips LS, Andersen J, Duncan E. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull. 2003;37 (3):99-117.
14. Groom MJ, Scerif G, Liddle PF et al. Effects of Motivation and Medication on Electrophysiological Markers of Response Inhibition in Children with Attention-Deficit/Hyperactivity Disorder. Biol Psychiatry, PMID: 19914599. 2009.
15. D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature Pharmacopsychiatry. 2004;37(1):1-11.
16. Starrenburg FC, Bogers JP. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry. 2009;24 (3):164-70.
17. Nakano T, Ito H. Epidemiology of diabetes mellitus in old age in Japan. Diabetes Res Clin Pract. 2007;1:76-81.
18. du Prel JB, Icks A, Grabert M, et al. Socioeconomic conditions and type 1 diabetes in childhood in North Rhine-Westphalia, Germany. Diabetologia. 2007;50:720-8.
19. Płaczkiewicz-Jankowska E, Szybiński Z, Huszno B. Environmental factors in the development of type 1 diabetes-a new insight. Prz Lek. 2007;64:175-9.
20. Golubnitschaja O. Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids. 2007;32:359-71.
21. Niwa Y, Ishimoto K, Kanoh T. Induction of superoxide dismutase in leukocytes by paraquat: correlation with age and possible predictor of longevity. Blood. 1990;76:835-41.
22. Koehn J, Turhani D, Krapfenbauer K. Potential Predictive Biomarkers for the Dysfunction of ß-cells in Type 2 Diabetes. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
23. Koehn J, Krapfenbauer K. Advanced proteomics procedure as a detection tool for predictive screening in type 2 pre-Diabetes. The EPMA-Journal 1. 2010.
24. Lesgards JF, Durand P, Lassarre M, et al. Assessment of lifestyle effects on the overall antioxidant capacity of healthy subjects. Environ Health Perspect. 2002;110:479-86.
25. Harrison PT. Application of gene therapy in diabetes care. Infect Disord Drug Targets. 2008;8:129-33.
26. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603.
27. George B, Cebioglu M, Yeghiazaryan K. Inadequate diabetes care: global figures cry for preventive measures and personalized treatment. The EPMA-Journal 1. 2010.
28. Josifova T, Schneider U, Henrich PB, et al. Eye disorders in diabetes: potential drug targets. Infect Disord Drug Targets. 2008;8:70-5.
29. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61.
30. Said G, Baudoin D, Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol. 2008;255(11):1693-702.
31. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics. 2009;6 (4):638-47.
32. Bailey CC, Sparrow JM. Co-morbidity in patients with sightthreatening diabetic retinopathy. Eye (Lond). 2001;15(Pt 6):719-22.
33. Kapalla M, Yeghiazaryan K, Hricová M, et al. Combined analysis of biochemical parameters in serum and differential gene expression in circulating leukocytes may serve as an ex vivo monitoring system to estimate risk factors for complications in Diabetes mellitus. Amino Acids. 2005;28:221-7.
34. Javadi MA, Katibeh M, Rafati N, et al. Prevalence of diabetic retinopathy in Tehran province: a population-based study. BMC Ophthalmol. 2009;16:9-12.
35. Mozaffari MS, Abdelsayed R, Schaffer SW. Diabetic Complications: Pathogenetic Mechanisms and Prognostic Indicators. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
36. Yeghiazaryan K, Bauriedel G, Schild HH, et al. Prediction of degeneration of native and bioprosthetic aortic valves: issuerelated particularities of diabetes mellitus. Infect Disord Drug Targets. 2008;8:88-99.
37. Handel AE, Handunnetthi L, Ebers GC, Ramagopalan SV. Type 1 diabetes mellitus and multiple sclerosis: common etiological features. Nat Rev Endocrinol. 2009;5(12):655-64.
38. Silva KC, Rosales MA, Biswas SK, et al. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes. 2009;58 (6):1382-90.
39. Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol, PMID: 19692274. 2009.
40. Moroz N, Tong M, Longato L, et al. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. Alzheimers Dis. 2008;15(1):29-44.
41. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2 (6):1101-13.
42. de la Monte SM, Longato L, Tong M, et al. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10 (10):1049-60.
43. Tan GS, Wong TY, Fong CW, et al. Diabetes, metabolic abnormalities, and glaucoma. Arch Ophthalmol. 2009;127 (10):1354-61.
44. Cebioglu M, Schild HH, Golubnitschaja O. Cancer predisposition in Diabetics: Risk factors considered for predictive diagnostics and targeted preventive measures. The EPMA-Journal 1. 2010.
45. Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004;65:323-32.
46. Mayr M, Mayr U, Chung YL, et al. Vascular proteomics: linking proteomic and metabolomic changes. Proteomics. 2004;4:3751-61.
47. Gahan PB. Circulating nucleic acids in plasma and serum: roles in diagnosis and prognosis in diabetes and cancer. Infect Disord Drug Targets. 2008;8:100-8.
48. Gahan PB. Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
49. Abebe W, Mozaffari MS. Endothelial Dysfunction in Diabetes: Potential Application of Circulating Markers for Advanced Diagnostic and Prognostic Tools. The EPMA-Journal 1. 2010.
50. Al-Shabrawey M, Smith S. Prediction of Diabetic Retinopathy: Role of Oxidative Stress and Relevance of Apoptotic Biomarkers. The EPMA-Journal 1. 2010.
51. Golubnitschaja O Method for early diagnosis of proliferative diabetic retinopathy. International Patent No. 06115230.2. 2006.
52. Golubnitschaja O. Advanced Technologies for Prediction of Secondary Complications in Diabetes mellitus. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
53. Josifova T, Henrich PB, Schrader W. Prevalence, Targeted Treatment and Prevention of Eye Disorders in Diabetes. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
54. Josifova T, Henrich BP, Pleastina-Boryan I. Proliferative Diabetic Retinopathy: Predictive and Preventive Measures at Hypoxia Induced Retinal Changes. The EPMA-Journal 1. 2010.
55. Li Calzi S, Neu M, Shaw LC et al. Endothelial Progenitor Dysfunction in the Pathogenesis of Diabetic Retinopathy: Treatment Concept to Correct Diabetes-Associated Deficits. The EPMA-Journal 1. 2010.
56. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79:1072-80.
57. Golubnitschaja O, Yeghiazaryan K, Skowasch D, et al. G. p21WAF1/CIP1 and 14-3-3 sigma gene expression in degenerated aortic valves: a link between cell cycle checkpoints and calcification. Amino Acids. 2006;31:309-16.
58. Yeghiazaryan K, Skowasch D, Bauriedel G, et al. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Amino Acids. 2007;32:109-14.
59. Yeghiazaryan K, Skowasch D, Bauriedel G, et al. Prediction of Degeneration of Native and Bioprosthetic Aortic Valves. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
60. Baban B, Penberthy WT, Mozaffari MS. The potential Role of Indoleamine-2,3-Dioxygenase (IDO) as a Predictive and Therapeutic Target for Diabetes Treatment: A Mythical Truth. The EPMA-Journal 1. 2010.
61. Elmarakby AA, Abdelsayed R, Liu JY et al. Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy. The EPMA-Journal 1. 2010.
62. Coelho JF, Ferreira P, Gil MH. New approaches in drug delivery systems: application for diabetes treatment. Infect Disord Drug Targets. 2008;8:119-28.
63. Coelho JFJ, Ferreira P, Fonseca AC, et al. Advanced Drug Delivery Systems in Diabetes Treatment. In: Golubnitschaja O, editor. Predictive Diagnostics and Personalized Treatment: Dream or Reality? New York: Nova Science Publishers; 2009.
64. Coelho J, Ferreira P, Alves P et al. Drug delivery systems: advanced technologies potentially applicable in personalized treatments. The EPMA-Journal 1. 2010.
65. Sena CM, Bento CF, Pereira P et al. Diabetes mellitus: new challenges and innovative therapies. The EPMA-Journal 1. 2010.
66. Zenoni S, Comi N, Fontana P. Individualized treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes. The EPMA-Journal 1. 2010.
67. Schrader WF, Josifova T. The options to minimize the surgical trauma to treat ocular diabetic complications and to improve postoperative recovery and quality of life require an individualized approach. The EPMA-Journal 1. 2010.
68. Hanes PhJ, Krishna R. Characteristics of inflammation common to both diabetes and periodontitis: are predictive diagnosis and targeted preventive measures possible? The EPMA-Journal 1. 2010.